Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04876495
Other study ID # VRE1516-1375
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 20, 2018
Est. completion date February 19, 2021

Study information

Verified date May 2021
Source University of Westminster
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

INTRODUCTION: Global protein consumption has been increasing for decades due to changes in socio-economic demographics and consumer trends towards higher protein intake, which may be related to their health benefits in performance nutrition and appetite regulation. The additional intake of protein often occurs in the form of supplements. One of the main ingredients used in sports and weight loss supplements are animal-derived proteins such as whey, which are of high quality, containing all the essential amino acids required in human nutrition with a high absorption rate. However, whey protein has a high environmental footprint, and it may contribute to insulin resistance in susceptible groups (e.g. obese, T2DM, insulin resistant, or those with sarcopenic obesity). Rice and potato protein isolates are high-quality plant proteins containing all essential amino acids comparably to whey protein. These plant-derived proteins may provide a more sustainable and accessible alternative to animal-derived proteins for appetite regulation and weight management.


Description:

Intervention study with three treatment groups in a randomised, single-blind, triple crossover design. Study population: Healthy male participants will receive three different isocaloric and -volumetric protein shakes prepared using whey, rice and potato protein powders on different trial days with at least a one-week washout period apart. Biological samples (blood and saliva samples) are collected at various time points during the visit. Blood samples are collected at baseline 10 min prior (T-10), then at 30 min (T30), 60 min (T60), 120 min (T120) and at 180 min (T180) after protein shake consumption. Saliva samples are collected at baseline (T-10), then at every 30 minutes following protein shake consumption (T30, T60, T90, T120, T150, T180). In addition, pertinent questionnaires Visual Analogue Scale [VAS] for the assessment of satiety and VAS for the assessment of protein shakes' perception will be collected at T-10, T30, T60, T90, T120, T150, T180 and at T0, respectively


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date February 19, 2021
Est. primary completion date February 19, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Males (18-65 years of age) - Healthy subjects Exclusion Criteria: - <18 years or >65 years - Consumption of >21 units of alcohol/week - Dieters - Any allergies/health issues related to items being ingested - Any serious illnesses or those on medication - Any illness affecting taste or appetite - Any gastrointestinal disorders - Any eating disorders - Any depression/mental disorders - Smoking

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Whey protein isolate
Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake. Other ingredients in the whey protein shake: Tropicana Trop50 Orange Juice 207mL Water 43 mL Sucralose 0.5g The total energy 233.47Kcal. Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.
Potato protein isolate
Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake. Other ingredients in the potato protein shake: Tropicana Trop50 Orange Juice 250mL Sucralose 0.5g The total energy 233.46Kcal Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.
Rice protein isolate
Oryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake. Other ingredients in the rice protein shake: Tropicana Trop50 Orange Juice 183mL Water 67mL Sucralose 0.5g The total energy 233.43Kcal Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.

Locations

Country Name City State
United Kingdom University of Westminster London Greater London

Sponsors (2)

Lead Sponsor Collaborator
University of Westminster Coventry University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T-10) Marker: glucose (mmol/L) Glucose measured 10 minutes prior to protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T30) Marker: glucose (mmol/L) Glucose measured 30 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T60) Marker: glucose (mmol/L) Glucose measured 60 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T120) Marker: glucose (mmol/L) Glucose measured 120 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T180) Marker: glucose (mmol/L) Glucose measured 180 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T-10) Marker: insulin (ng/mL) Insulin measured 10 minutes prior to protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T30) Marker: insulin (ng/mL) Insulin measured 30 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T60) Marker: insulin (ng/mL) Insulin measured 60 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T120) Marker: insulin (ng/mL) Insulin measured 120 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T180) Marker: insulin (ng/mL) Insulin measured 180 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T-10) Markers: glucagon-like peptide 1 (pM) Glucagon-like peptide 1 measured 10 minutes prior to protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T30) Markers: glucagon-like peptide 1 (pM) Glucagon-like peptide 1 measured 30 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T60) Markers: glucagon-like peptide 1 (pM) Glucagon-like peptide 1 measured 60 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T120) Markers: glucagon-like peptide 1 (pM) Glucagon-like peptide 1 measured 120 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T180) Markers: glucagon-like peptide 1 (pM) Glucagon-like peptide 1 measured 180 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T-10) Markers: peptide tyrosine tyrosine (pg/mL) Peptide tyrosine tyrosine measured 10 minutes prior to protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T30) Markers: peptide tyrosine tyrosine (pg/mL) Peptide tyrosine tyrosine measured 30 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T60) Markers: peptide tyrosine tyrosine (pg/mL) Peptide tyrosine tyrosine measured 60 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T120) Markers: peptide tyrosine tyrosine (pg/mL) Peptide tyrosine tyrosine measured 120 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T180) Markers: peptide tyrosine tyrosine (pg/mL) Peptide tyrosine tyrosine measured 180 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T-10) Markers: ghrelin (pg/mL) Ghrelin (pg/mL) measured 10 minutes prior to protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T30) Markers: ghrelin (pg/mL) Ghrelin (pg/mL) measured 30 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T60) Markers: ghrelin (pg/mL) Ghrelin (pg/mL) measured 60 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T120) Markers: ghrelin (pg/mL) Ghrelin (pg/mL) measured 120 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T180) Markers: ghrelin (pg/mL) Ghrelin (pg/mL) measured 180 minutes post protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T-10) Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite) Visual Analogue Scale for Appetite (VAS-A) collected immediately prior to protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T30) Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite) Visual Analogue Scale for Appetite (VAS-A) collected 30 minutes after protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T60) Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite) Visual Analogue Scale for Appetite (VAS-A) collected 60 minutes after protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T90) Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite) Visual Analogue Scale for Appetite (VAS-A) collected 90 minutes after protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T120) Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite) Visual Analogue Scale for Appetite (VAS-A) collected 120 minutes after protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T150) Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite) Visual Analogue Scale for Appetite (VAS-A) collected 150 minutes after protein shake consumption
Primary To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T180) Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite) Visual Analogue Scale for Appetite (VAS-A) collected 180 minutes after protein shake consumption
Secondary To assess the perception of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® Subjective analysis including: Visual Analogue Scale for Palatability (VAS-P). Scores range from 0 to 100 (the higher the score the lower the palatability) VAS for Palatability collected immediately after protein shake consumption
See also
  Status Clinical Trial Phase
Completed NCT06146322 - Barley Beta-glucan, Glycemic Control, and Appetite N/A
Completed NCT01900340 - Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans Phase 1
Completed NCT02285907 - Protein Quality on Appetite Control, Reward-driven Eating, & Subsequent Food Intake N/A
Completed NCT01354600 - Effects of Positive Energy Balance and Exercise on Appetite Hormones in Sedentary Men and Women N/A
Suspended NCT03031132 - The Effects of a High Protein Breakfast on Appetite and Sleep in Young Adults N/A
Recruiting NCT03009695 - Transcranial Magnetic Stimulation (TMS) in Obesity N/A
Recruiting NCT02075827 - Metabolic Response to Playing Video Games: Two Arm Trial N/A
Withdrawn NCT01946841 - Specific Enteral Nutrition in Malnourished, Dialysis Patients With Chronic Kidney Disease. Efficacy, Safety, Quality of Life Phase 2
Completed NCT01088841 - Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY Phase 1